RVMD Revolution Medicines Corp Gross Profitability

Official company branding of RevMed (RVMD)

Investing in Revolution Medicines (RVMD) carries the risk of clinical trial failure and a lack of stable revenue streams. The business's success depends on FDA approval of RAS inhibitors and the rate of cash burn. The company's gross profit margin demonstrates the effectiveness of targeted therapy, while the 90.30 metric serves as the target level for assessing the potential of innovative drugs.

Revolution Medicines Corp (RVMD) Return on Gross Profit: for the period 07/04/2022 - 11/20/2026

Analytical breakdowns and data insights for company Revolution Medicines Inc (RVMD)

- stock value and consensus price forecast:
Basic company analysis:RevMed
Mass-produced product of Revolution Medicines, Inc.

Gross margin measures profit generation efficiency by determining the portion of revenue remaining after covering direct production costs. By analyzing the gross profit margin, an investor assesses the business's pricing power, which is critical for Revolution Medicines (RVMD) due to its total reliance on external contract research organizations (CRO) for drug manufacturing and the conduct of clinical trials.

Key competitors

Gross Profit Margin BeiGene Ltd. (ONC)|Return on Gross Profit HALO|Gross Return on Sales AAPG (Ascentage Pharma Group)|Gross Margin CGON|UroGen Pharma - Gross Return on Sales|Bicara Therapeutics - Return on Gross Profit|Gross Margin Personalis Inc PSNL|Erasca Oncology - Gross Margin|Gross Profit Rate DCTH (Delcath Corp)|YMAB: Gross Margin|AURA - Return on Sales by Gross Profit|CADL (Candel Therapeutics Inc.) - Gross Margin|Gross Return on Sales ARAY (Accuray)|Return on Gross Profit SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Gross Profit Margin|Gross Profitability Citius Oncology, Inc. CTOR|HURA - Return on Gross Profit|protaratx.com - Gross Margin|FATE - Gross Margin|WHWK: Gross Margin|TScan Therapeutics (TCRX) - Gross Margin|Gross Profitability Champions Oncology|Gross Profitability XBIT|Gross Margin CVM|Return on Gross Profit OS Therapies Inc. OSTX|Gross Profitability Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Gross Profit Margin|ANL - Gross Profitability|Gross Profit Margin verupharma.com|TPST: Gross Margin|XLO - Return on Sales by Gross Profit|Gross Profitability Renovaro|Gross Margin muraloncology.com|Gross Margin KAPA|Return on Sales by Gross Profit OnKure Therapeutics, Inc.|Gross Margin GDTC (w2.cytomed.sg)|CRIS - Return on Gross Profit|Apollomics - Gross Margin|Tharimmune Corp (THAR) - Return on Gross Profit|ADVB: Gross Margin|Return on Gross Profit Genprex|CLDI (Calidi Biotherapeutics, Inc.) - Gross Margin|Gross Return on Sales SBFM (Sunshine Biopharma)|Gross Profitability Xenetic Bio (XBIO)|Gross Profitability SLRX (Salarius Pharma)|Kitov Pharma - Return on Gross Profit|American Oncology Network (AONC) - Gross Profit Margin|BeiGene - Gross Margin|Checkpoint Therapeutics, Inc. (CKPT) - Return on Gross Profit|ELEV (Elevation Oncology, Inc.) - Return on Gross Profit|iCAD Inc. - Gross Profit Rate|Return on Gross Profit IKNA|Gross Margin notablelabs.com|Return on Gross Profit VIRX (Viracta Therapeutics Inc.)|MOR - Gross Profit Margin|Gross Profitability NAYA Biosciences NAYA|AAPGV - Return on Gross Profit